Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Alvogen has entered into a definitive agreement to acquire a portfolio of four pharmaceutical products from Pfizer for marketing in the US.
Subscribe to our email newsletter
In the US market, Alvogen has a pipeline of more than 60 ANDA’s, of which 28 have first-to-file or first-to-market potential.
The deal will further diversify and strengthen Alvogen’s commercial platform in the US market as well as create new opportunities for continued growth across the region.
The acquired portfolio includes three injectable products and one inhaled solution product divested by Pfizer as a precondition to its closing of the acquisition of Hospira.
Alvogen chairman and CEO Robert Wessman said: "This acquisition supports our strategy to gain exposure to the high growth, injectable segment in the US market.
"These products will complement as well as significantly strengthen our existing portfolio, further enhancing our customer offering.
"We will be able to leverage our current sales and marketing network to increase market share in the US. Moreover, this important strategic development takes Alvogen closer towards its stated ambition to become one of the leading global players."
Of the acquired assets, two are on-market products, clindamycin injection and acetylcysteine inhalation solution.
According to Alvogen, acetylcysteine will continue to be marketed by Fresenius with the company receiving profit sharing payments.
Additionally, Alvogen will acquire two pending ANDA’s, Voriconazole injection and Melphalan injection, which represent generic market with limited participation and are expected to launch as early as 2016.